Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research

Berhani, Orit; Glasner, Ariella; Kahlon, Shira; Duev‐Cohen, Alexandra; Yamin, Rachel; Horwitz, Elad; Enk, Jonatan; Moshel, Ofra; Varvak, Alexandar; Porgador, Angel; Jonjić, Stipan; Mandelboim, Ofer

doi:10.1002/eji.201847611

prikaz prve stranice dokumenta Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research

Scientific paper - Original scientific paper

Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research

European Journal of Immunology, 49 (2018), 2; 228-241. https://doi.org/10.1002/eji.201847611

Berhani, Orit; Glasner, Ariella; Kahlon, Shira; Duev‐Cohen, Alexandra; Yamin, Rachel; Horwitz, Elad; Enk, Jonatan; Moshel, Ofra; Varvak, Alexandar; Porgador, Angel; Jonjić, Stipan; Mandelboim, Ofer

Cite this document

APA 6th Edition

Berhani, O., Glasner, A., Kahlon, S., Duev‐Cohen, A., Yamin, R., Horwitz, E. ... Mandelboim, O. (2018). Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research. European Journal of Immunology, 49. (2), 228-241. doi: 10.1002/eji.201847611

MLA 8th Edition

Berhani, Orit, et al. "Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research." European Journal of Immunology, vol. 49, no. 2, 2018, pp. 228-241. https://doi.org/10.1002/eji.201847611

Chicago 17th Edition

Berhani, Orit, Ariella Glasner, Shira Kahlon, Alexandra Duev‐Cohen, Rachel Yamin, Elad Horwitz, Jonatan Enk, et al. "Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research." European Journal of Immunology 49, no. 2 (2018): 228-241. https://doi.org/10.1002/eji.201847611

Harvard

Berhani, O., et al. (2018) 'Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research', European Journal of Immunology, 49(2), pp. 228-241. doi: 10.1002/eji.201847611

Vancouver

Berhani O, Glasner A, Kahlon S, Duev‐Cohen A, Yamin R, Horwitz E, and sur.. Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research. European Journal of Immunology [Internet]. 2018 December 17 [cited 2024 September 09];49(2):228-241. doi: 10.1002/eji.201847611

IEEE

O. Berhani, et al., "Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research", European Journal of Immunology, vol. 49, no. 2, pp. 228-241, December 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:846941. [Accessed: 09 September 2024]

Cite this item: https://urn.nsk.hr/urn:nbn:hr:184:846941

Please login to the repository to save this object to your list.

Metadata

Title (english)	Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research
Author	Orit Berhani
Author	Ariella Glasner
Author	Shira Kahlon
Author	Alexandra Duev‐Cohen
Author	Rachel Yamin
Author	Elad Horwitz
Author	Jonatan Enk
Author	Ofra Moshel
Author	Alexandar Varvak
Author	Angel Porgador
Author	Stipan Jonjić
Author	Ofer Mandelboim
Author's institution	University of Rijeka Faculty of Medicine (Center for Proteomics)
Author's institution	University of Rijeka Faculty of Medicine (Department of Histology and Embryology)
Scientific / art field, discipline and subdiscipline	BIOMEDICINE AND HEALTHCARE Basic Medical Sciences
Abstract (english)	Natural killer (NK) cells are innate lymphocytes that efficiently eliminate cancerous and infected cells. NKp46 is an important NK activating receptor shown to participate in recognition and activation of NK cells against pathogens, tumor cells, virally infected cells, and self-cells in autoimmune conditions, including type I and II diabetes. However, some of the NKp46 ligands are unknown and therefore investigating human NKp46 activity and its critical role in NK cell biology is problematic. We developed a unique anti-human NKp46 monocloncal antibody, denoted hNKp46.02 (02). The 02 mAb can induce receptor internalization and degradation. By binding to a unique epitope on a particular domain of NKp46, 02 lead NKp46 to lysosomal degradation. This downregulation therefore enables the investigation of all NKp46 activities. Indeed, using the 02 mAb we determined NK cell targets which are critically dependent on NKp46 activity, including certain tumor cells lines and human pancreatic beta cells. Most importantly, we showed that a toxin-conjugated 02 inhibits the growth of NKp46-positive cells; thus, exemplifying the potential of 02 in becoming an immunotherapeutic drug to treat NKp46-dependent diseases, such as, type I diabetes and NK and T cell related malignancies.
Keywords (english)
Language	english
Publication type	Scientific paper - Original scientific paper
Publication status	Published
Peer review	Peer review - international
Publication version	Published version
Journal title	European Journal of Immunology
Numbering	vol. 49, no. 2, pp. 228-241
p-ISSN	0014-2980
e-ISSN	1521-4141
DOI	https://doi.org/10.1002/eji.201847611
URN:NBN	urn:nbn:hr:184:846941
Publication	2018-12-17
Document URL	https://onlinelibrary.wiley.com/doi/10.1002/eji.201847611
Type of resource	Text
Access conditions	Open access
Terms of use
Created on	2022-02-21 17:12:07